SEC Comment Letter for Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Feb 11, 2019
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: Feb. 11, 2019 · CIK: 0001583771 · Accession: 0000000000-19-001897
AI Filing Summary & Sentiment
File numbers found in text: 333-229416
Letter
February 11, 2019 Robert Foster Chief Executive Officer ContraVir Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 Re:ContraVir Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed on January 29, 2019 File No. 333-229416 Dear Mr. Foster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Todd Schiffman at 202-551-3491 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
February 11, 2019
Robert Foster
Chief Executive Officer
ContraVir Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, NJ 08837
Re:ContraVir Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed on January 29, 2019
File No. 333-229416
Dear Mr. Foster:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Todd Schiffman at 202-551-3491 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance